Detalhe da pesquisa
1.
Neurologic complications of breast cancer.
Cancer
; 129(4): 505-520, 2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36537474
2.
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Oncologist
; 28(10): 919-e972, 2023 10 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37279797
3.
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Future Oncol
; 16(14): 899-909, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32270710
4.
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Curr Oncol Rep
; 21(12): 109, 2019 11 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31781874
5.
Analysis of breast cancer in young women in the Department of Defense (DOD) database.
Breast Cancer Res Treat
; 168(2): 501-511, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29247440
6.
Update on PARP Inhibitors in Breast Cancer.
Curr Treat Options Oncol
; 19(5): 21, 2018 04 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29644491
7.
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Clin Cancer Res
; 29(8): 1450-1459, 2023 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36705597
8.
HER2-positive breast cancer brain metastasis: A new and exciting landscape.
Cancer Rep (Hoboken)
; 5(4): e1274, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32881421
9.
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.
Pract Radiat Oncol
; 12(4): 265-282, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35534352
10.
"Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic".
Cancer J
; 27(1): 76-82, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33475296
11.
HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker.
Neuro Oncol
; 22(11): 1625-1636, 2020 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32386414
12.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
J Immunother Cancer
; 7(1): 197, 2019 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-31345267
13.
Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.
J Mol Med (Berl)
; 93(1): 13-29, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25412774